Suven reports positive Phase 2b results for Ropanicant in major depressive disorder

Suven has already begun planning a global Phase 3 registrational program for MDD based on the results

Bayer seals $300 million Perfuse deal

Secures high-stakes glaucoma drug in up to $2.45b bet on eye care pipeline

Indian Pharmacopoeia Commission delegation attends WHO-led international meet in Brazil

Highlights India’s advances in pharmacopoeial science, regulatory standards, and global harmonization efforts at the 16th International Meeting of World Pharmacopoeias

We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene

Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships

Orionis expands Novartis partnership in potential $1.4 billion molecular glue drug feal

Mabion reactivates MabionCD20 through rare disease collaboration with Oddifact

MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies

Biopharma SHAKTI envisages launch of 100 biologics by 2047: Anupriya Patel

The union minister spoke at the 2nd Pharma Summit & Awards 2026 organised by ASSOCHAM in New Delhi

Sygnature Discovery partners with DaltonTx to enhance AI-driven drug discovery capabilities

Collaboration aims to accelerate medicinal chemistry decision-making, reduce synthesis burden and strengthen data-secure AI adoption in drug discovery

HAB Pharma targets Rs. 3,000 crore revenue by 2030

Consolidated entity plans to strengthen specialty pharmaceutical offerings, expand manufacturing capacity, and accelerate global market penetration across emerging regions

Axplora consolidates global UDCA manufacturing at Vizag facility

Strategic shift from Italy to India strengthens supply chain resilience, expands capacity and enhances sustainability for the growing global UDCA market